Previous 10 |
SAN FRANCISCO , Oct. 5, 2018 /PRNewswire/ -- Conference call and webcast Friday, October 5, 2018 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (internationa...
SAN FRANCISCO , Oct. 5, 2018 /PRNewswire/ -- Conference call and webcast Friday, October 5, 2018 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (internation...
SAN FRANCISCO , Oct. 3, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-F...
Quick Take LogicBio Therapeutics ( LOGC ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing treatments for rare genetic diseases associated with the liver. LOGC is an extremely early stage biopharma; ...
SAN FRANCISCO , Sept. 26, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will...
News, Short Squeeze, Breakout and More Instantly...
Audentes Therapeutics Inc. Company Name:
BOLD Stock Symbol:
NASDAQ Market:
Audentes Therapeutics Inc. Website:
Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer,...
BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will...